Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TELA Bio (TELA)
NASDAQ:TELA
Holding TELA?
Track your performance easily
Earnings Data
Report Date
Mar 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.53Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2020
|% Change Since: -10.03%
|Next Earnings Date:Dec 18, 2019
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and market expansion, particularly in Europe, along with a successful public offering and operational improvements. However, there were concerns about decreased gross margins, increased sales and marketing expenses, and ongoing net losses. The company remains optimistic with positive revenue guidance for the full year.Company Guidance
During the TELA Bio Q3 2024 earnings call, the company provided guidance reflecting a robust performance with a 26% year-over-year revenue growth, reaching $19 million for the quarter. Sales of OviTex and OviTex PRS increased by 39% and 44% respectively, while the European business expanded by 67%. The company achieved over $300,000 in global average daily sales and secured $43 million from a public offering, enhancing its financial position. Operational improvements translated into expected annualized OpEx reductions of $5 to $10 million, with profitability anticipated due to these savings and increased revenue. TELA Bio reaffirmed its full-year revenue guidance of $74.5 to $76.5 million, representing a 28% to 31% increase over 2023, despite potential challenges from IV fluid shortages.Strong Revenue Growth
Revenue for Q3 was $19 million, a 26% year-over-year increase. Unit sales for OviTex and OviTex PRS grew 39% and 44%, respectively.
European Market Expansion
European business grew 67% from the prior year period, with the first $1 million month in Europe achieved.
Successful Public Offering
Closed a public offering that added $43 million in cash to the balance sheet.
Operational Improvements
Implemented changes expected to annualize to $5 to $10 million in OpEx reduction.
Positive Guidance for 2024
On track to achieve full year revenue guidance of $74.5 million to $76.5 million, reflecting growth of 28% to 31% over 2023.
---
TELA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TELA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $2.99 | $3.08 | +3.01% |
| Aug 12, 2024 | $4.01 | $3.09 | -22.94% |
| May 09, 2024 | $4.94 | $5.77 | +16.80% |
| Mar 21, 2024 | $5.51 | $5.35 | -2.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does TELA Bio (TELA) report earnings?
TELA Bio (TELA) is schdueled to report earning on Mar 19, 2025, TBA Not Confirmed.
What is TELA Bio (TELA) earnings time?
TELA Bio (TELA) earnings time is at Mar 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TELA EPS forecast?
TELA EPS forecast for the fiscal quarter 2024 (Q4) is -0.21.
---